UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13D

THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 20)*

Avalo Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share (Title of Class of Securities)

05338F108 (CUSIP Number)

Brian Kohn
c/o Armistice Capital, LLC
510 Madison Avenue
7th Floor
New York, NY 10022
Telephone Number: (212) 231-4930
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 14, 2021 (Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box \Box

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

CUSIP No. 05338F108

1	NAMES OF REPORTING PERSONS						
	Armistice Capital, LLC						
2	A 1						
	(a) (b) (
3	SEC USE ONLY						
4	COVER OF AN AND A COPE DISTRICTION OF						
4	4 SOURCE OF FUNDS (SEE INSTRUCTIONS)						
	AF						
5							
	CITIZENGLID	OD D	LACE OF ORGANIZATION				
6	CITIZENSHIP	OK P	LACE OF ORGANIZATION				
	Delaware						
- !		7	SOLE VOTING POWER				
]	NUMBER OF		0				
Di	SHARES	8	SHARED VOTING POWER				
	ENEFICIALLY OWNED BY		49,000,000				
EACH		9	SOLE DISPOSITIVE POWER				
REPORTING							
	PERSON WITH						
WIII		10	SHARED DISPOSITIVE POWER				
			49,000,000				
11	AGGREGATE	AMO	UNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
12	49,000,000 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
12	2 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
13	PERCENT OF	CLAS	S REPRESENTED BY AMOUNT IN ROW (11)				
	42.60/						
14	43.6%						
14	4 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)						
	IA, OO						
	•						

CUSIP No. 05338F108

1	NAMES OF REPORTING PERSONS						
	Steven Boyd						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP						
-	(a) □ (b)						
3	3 SEC USE ONLY						
4	SOURCE OF F	UNDS (SEE INSTRUCTIONS)					
5	AF	F DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)					
3	CHECK BOX	IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO THEM 2(D) OR 2(E)					
6	CITIZENSHIP	OR PLACE OF ORGANIZATION					
	United States of America						
		7 SOLE VOTING POWER					
		412,442					
]	NUMBER OF	8 SHARED VOTING POWER					
RI	SHARES ENEFICIALLY	o Shakeb vollagiowek					
OWNED BY		49,000,000					
	EACH	9 SOLE DISPOSITIVE POWER					
REPORTING							
	PERSON WITH	412,442					
	.,	10 SHARED DISPOSITIVE POWER					
		49,000,000					
11	AGGREGATE	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	49,412,442						
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)						
13	1 ERCENT OF	CENSE REPRESENTED DT ANIOUNT IN NOW (11)					
	43.9%						
14							
	IN, HC						

Amendment No. 20 to Schedule 13D

The following constitutes Amendment No. 20 to the Schedule 13D filed by the undersigned ("Amendment No. 20"). This Amendment No. 20 amends the Schedule 13D as specifically set forth herein.

All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

Item 4. Purpose of Transaction

Item 4 of the Schedule 13D is supplemented and superseded, as the case may be, as follows:

On October 14, 2021, pursuant to previously disclosed rights under the Certificate of Designation of Preferences, Rights and Limitations of the Issuer's Series A Convertible Preferred Stock, the Reporting Persons on behalf of the Master Fund, exercised the right to elect an additional director to the Issuer's Board of Directors (the "Board") and elected Keith Maher, MD, a Managing Director at Armistice Capital, LLC, to the Issuer's Board with immediate effect

SIGNATURE

	After reasonable inquiry and to the best of my	knowledge and belief, I c	ertify that the information	set forth in this statement is	true, complete and
corre	rt .				

October 14, 2021 (Date)

Armistice Capital, LLC

By: /s/ Steven Boyd Name: Steven Boyd Title: Managing Member

Steven Boyd

/s/ Steven Boyd